Acasti Pharma develops pharmaceutical products for rare diseases in Canada. Its lead product is GTX-104, an IV infusion to treat subarachnoid hemorrhage. It also works on GTX-102, a spray for ataxia-telangiectasia, and GTX-101, a topical spray for postherpetic neuralgia. The company was founded in 2002 and is based in New Jersey.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 3.2 |